Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 115Cholangiocarcinoma 24Carcinoma, Renal Cell 20Liver Neoplasms 12Stomach Neoplasms 10Biliary Tract Neoplasms 10Thyroid Neoplasms 8Endometrial Neoplasms 8Breast Neoplasms 8Neoplasms 7Recurrence 6Neuroendocrine Tumors 5Neoplasm Metastasis 5Melanoma 5Uterine Cervical Neoplasms 4Thyroid Carcinoma, Anaplastic 4Thyroid Cancer, Papillary 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma, Adenoid Cystic 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Adenocarcinoma 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2

Interventions

vandetanib 1sacubitril and valsartan sodium hydrate drug combination 1lenvatinib 1fluorodopa F 18 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid cancer, medullary × lenvatinib × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡